Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）
Trial Parameters
Brief Summary
Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.
Eligibility Criteria
Inclusion Criteria: * Patients admitted to the ICU between January 2021 and May 2024 and subsequently discharged * Age ≥ 18 years * Meeting the Sepsis-3.0 diagnostic criteria * Platelet count \< 100 × 10⁹/L at ICU admission * ICU length of stay ≥ 48 hours Exclusion Criteria: * Active bleeding (e.g., major gastrointestinal bleeding, intracranial hemorrhage) or hematologic malignancies (e.g., leukemia, myelodysplastic syndrome, lymphoma); * Liver cirrhosis (Child-Pugh class B/C), chronic kidney disease (CKD stage 4-5), or autoimmune diseases (e.g., systemic lupus erythematosus); * Receipt of chemotherapy, immunosuppressants (e.g., cyclosporine, rituximab), or hematopoietic stem cell/solid organ transplantation within 2 weeks; * Pregnancy or lactation; * Pre-existing chronic thrombocytopenia (baseline platelet count \<100×10⁹/L for \>1 month) or long-term use of antiplatelet/anticoagulant drugs (\>2 weeks); * Significant baseline coagulation dysfunction at ICU admission:Prothrombin time (